Study identifier:D4198C00001
ClinicalTrials.gov identifier:NCT02558894
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2
No
MEDI4736 monotherapy, tremelimumab+MEDI4736
All
65
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Jul 2018 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: MEDI4736 monotherapy MEDI4736 via IV infusion. | Drug: MEDI4736 monotherapy MEDI4736 via IV infusion. Other Name: NA |
Experimental: tremelimumab+MEDI4736 MEDI4736+tremelimumab via IV infusion. | Drug: tremelimumab+MEDI4736 tremelimumab+MEDI4736 via IV infusion. Other Name: NA |